Free Newsletter
MabThera nabs NICE nod for leukemia
Free newsletter via e-mail
Tools
The U.K.'s cost-effectiveness watchdog has recommended Roche's top-selling cancer drug MabThera as a first line treatment for the most common form of adult leukemia. NICE recommends that the National Health Service pay for MabThera treatment only in combination with two specific chemo drugs. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: